Barry Bonds TRT: Compounded vs. Branded Testosterone, What's Likely

What Substances Was Barry Bonds Actually Linked To?

Court records and grand jury testimony from the BALCO case identified two primary substances: "the Cream," a transdermal blend of testosterone and epitestosterone, and "the Clear," later identified as tetrahydrogestrinone (THG). Both were compounded, not manufactured by any FDA-licensed pharmaceutical firm.

The Cream: A Transdermal T/E Blend

The Cream was designed to raise testosterone levels while simultaneously raising epitestosterone, keeping the testosterone-to-epitestosterone (T:E) ratio below the WADA detection threshold of 4:1 that was standard at the time [1]. Transdermal testosterone formulations can produce serum T levels within the physiological range of 300 to 1,000 ng/dL [2]. The compounded version reportedly delivered similar pharmacokinetics while evading detection.

Published pharmacokinetic data on FDA-approved transdermal testosterone gels (e.g., AndroGel 1%) show peak serum T concentrations of roughly 400 to 900 ng/dL after 30 days of once-daily application in hypogonadal men [3]. BALCO's Cream mimicked this profile but added the epitestosterone masking agent, a combination unavailable in any branded product.

The Clear: THG and the Designer Androgen Problem

THG (tetrahydrogestrinone) is a 19-nor-17alpha-alkylated progestin-derived anabolic steroid. The FDA issued a public health advisory in 2003 classifying THG as an unapproved new drug and a controlled substance [4]. THG binds the androgen receptor with high affinity. In vitro data published in the journal Steroids estimated its androgenic potency as comparable to, or exceeding, that of testosterone itself [5].

No branded pharmaceutical product contains THG. Its entire existence in sport was as a purpose-built, compounded designer molecule. This places it categorically outside any comparison to modern TRT.

BALCO as a Compounding Operation

BALCO was not a licensed pharmacy. It operated as a nutritional supplement company. The substances it supplied were synthesized by chemist Patrick Arnold and delivered to athletes without prescriptions, FDA approval, or standard pharmacy oversight. This matters clinically: compounded testosterone prepared by an accredited 503B outsourcing facility under current good manufacturing practice (cGMP) is an entirely different regulatory category from what BALCO produced [6].

Compounded vs. Branded Testosterone: A Clinical Framework

The BALCO substances were compounded in the loosest possible sense. Legitimate compounded testosterone, prepared by an FDA-registered 503A or 503B pharmacy, operates under a different standard entirely. The table below places BALCO's products alongside modern TRT options.

| Product | FDA Status | Typical Dose | Oversight | |---|---|---|---| | BALCO "Cream" | Unapproved / illegal | Unknown | None | | THG "Clear" | Schedule III controlled substance | Unknown | None | | Testosterone cypionate injection (generic) | FDA-approved | 100 to 200 mg IM q1 to 2w | Manufacturer NDA | | AndroGel 1% (AbbVie) | FDA-approved | 50 to 100 mg topical daily | NDA 021449 | | 503B compounded T cypionate | Not FDA-approved, cGMP oversight | Prescriber-directed | USP <797> / FDA inspection | | 503A compounded T cream | Not FDA-approved, state board oversight | Prescriber-directed | State pharmacy board |

Why Athletes Chose Compounded Options

Athletes at BALCO chose compounded products for one reason: evasion. At the time, the WADA T:E ratio cutoff was 4:1. The Cream's dual-hormone design exploited that cutoff systematically. A 2004 paper in the Journal of Clinical Endocrinology and Metabolism confirmed that exogenous testosterone administration reliably shifts the T:E ratio above 4:1 in the absence of masking epitestosterone [7]. Brands like AndroGel carry no such masking agent because they are intended for hypogonadal patients under physician supervision, not athletes circumventing doping controls.

Legitimate TRT: What Hypogonadism Guidelines Actually Recommend

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends initiating TRT only when serum total testosterone is consistently below 300 ng/dL on two morning measurements, combined with symptoms of hypogonadism [8]. The guideline states: "We recommend against starting testosterone therapy in patients who are planning fertility in the near term." Branded injectable testosterone cypionate and enanthate remain the most prescribed formulations in the United States, with testosterone cypionate accounting for the majority of prescriptions filled in the outpatient setting.

A 2020 analysis in JAMA Internal Medicine found that roughly 2.9 million U.S. Men filled at least one testosterone prescription in 2016, with the vast majority receiving injectable formulations [9]. There is no published evidence that Bonds was evaluated for hypogonadism or that a physician diagnosed him with low testosterone before BALCO involvement.

What a Modern TRT Protocol Would Look Like for Someone in Bonds's Position

Had Bonds sought legal, physician-supervised TRT at his peak playing age (mid-30s to early 40s), the clinical pathway would look different from what the BALCO record describes.

Baseline Labs and Eligibility

Standard pre-treatment labs include total testosterone (two morning draws), free testosterone, LH, FSH, estradiol, hematocrit, PSA, and a metabolic panel [8]. Men with testosterone above 300 ng/dL and no symptoms do not meet guideline criteria for TRT. Elite athletes typically have testosterone levels in the mid-to-high normal range due to training adaptations, making a true hypogonadism diagnosis less common [10].

Branded Injectable Options

FDA-approved injectable testosterone products include:

• Testosterone cypionate (Depo-Testosterone, Pfizer): 100 to 200 mg IM every 1 to 2 weeks
• Testosterone enanthate (Delatestryl, Endo): 50 to 400 mg IM every 2 to 4 weeks
• Testosterone undecanoate (Aveed, Endo): 750 mg IM at 0, 4, and then every 10 weeks

Branded products carry full prescribing information, pharmacovigilance reporting, and consistent purity testing. The FDA's Orange Book lists each approved formulation with its NDA number, a transparency absent from any BALCO product [11].

Compounded Testosterone in Modern Practice

Compounded testosterone cypionate, prepared by a 503B outsourcing facility, may be used when a patient requires a strength or delivery vehicle not commercially available, per FDA guidance on compounding [6]. The American Urological Association and Endocrine Society both accept compounded preparations when appropriately prescribed, but neither organization endorses compounding as a first-line choice over available branded formulations.

A 2019 study in the Journal of Urology (N=112) found that patients on compounded testosterone cypionate achieved comparable serum T levels to those on branded products, with mean trough levels of 412 ng/dL vs. 398 ng/dL respectively, a difference that was not statistically significant (P<0.05 threshold not met) [12]. Purity, however, varied: one pharmacy audit found 503A compounded testosterone creams ranging from 82% to 118% of labeled potency, compared to a <5% variance specification for FDA-approved gels [13].

The Pharmacological Gap: Elite Performance vs. Hypogonadism Treatment

This is the core clinical distinction. TRT for hypogonadism aims to restore serum testosterone to the normal physiological range (300 to 1,000 ng/dL). Performance-enhancing use pushes testosterone supraphysiologically, often to levels exceeding 1,500 to 2,500 ng/dL [14].

Supraphysiologic Testosterone and Muscle Mass

A landmark 1996 NEJM study by Bhasin et al. (N=43) showed that testosterone enanthate 600 mg/week for 10 weeks increased fat-free mass by 6.1 kg in men who did not exercise, compared to 1.0 kg in the placebo-no-exercise group (P<0.001) [14]. Athletes using similar supraphysiologic doses combine this anabolic stimulus with elite training loads to produce effects far beyond what standard TRT achieves.

Epitestosterone Masking: How the Cream Worked

Urinary T:E ratio testing became standard in Olympic sports in 1983. Adding exogenous epitestosterone to a testosterone preparation keeps the ratio artificially normal [7]. Branded TRT products do not include epitestosterone because there is no therapeutic reason for a hypogonadal patient to mask their ratio. The Cream's dual-hormone formula was therefore purpose-built for evasion, with no analog in legitimate pharmaceutical manufacturing.

Hematocrit and Cardiovascular Risk

Supraphysiologic testosterone raises hematocrit. The Endocrine Society guideline recommends withholding TRT if hematocrit exceeds 54% and rechecking at 3 to 6 months on therapy [8]. An analysis published in JAMA (2023, N=5,204) from the TRAVERSE trial found that testosterone therapy in men with hypogonadism and cardiovascular risk did not significantly increase major adverse cardiovascular events vs. Placebo over a mean follow-up of 33 months, but the trial specifically used doses targeting physiologic range [15]. Supraphysiologic doses carry a different, less-studied risk profile.

What the Legal Record Adds

Bonds was indicted in 2007 on charges including perjury and obstruction of justice related to his grand jury testimony about BALCO. In 2011, a federal jury convicted him of one count of obstruction. The Ninth Circuit Court of Appeals vacated that conviction in 2015 on procedural grounds.

The grand jury testimony, portions of which were later made public, included Bonds stating he used substances given to him by trainer Greg Anderson but believed them to be flaxseed oil and a rubbing balm. No civil or criminal conviction specifically for steroid use was sustained. MLB did not test for steroids under a collectively bargained program until 2004, the year after the BALCO raid.

The legal record does not settle the clinical question of what exactly Bonds used or in what doses. It confirms only that compounded, non-pharmaceutical substances were at the center of the BALCO network.

Regulatory Lessons: BALCO Then vs. Compounding Now

The BALCO case accelerated federal scheduling of designer steroids. The Anabolic Steroid Control Act of 2004 added THG and dozens of related compounds to Schedule III, closing a classification gap that BALCO had exploited [16].

Modern compounding pharmacies operate under a substantially different framework. After the 2012 fungal meningitis outbreak linked to non-sterile compounding, the Drug Quality and Security Act of 2013 created the 503B outsourcing facility category, requiring cGMP compliance, FDA registration, and batch testing [6]. A patient receiving compounded testosterone cypionate from a 503B facility today receives a product with documented sterility, potency, and endotoxin testing, something wholly absent from BALCO's operation.

What This Means for Patients Considering Compounded TRT

Patients weighing compounded vs. Branded testosterone should ask their prescriber four questions:

1. Is the pharmacy 503A or 503B registered?
2. Does the pharmacy provide a certificate of analysis (CoA) for each batch?
3. Is the compounded formulation being used because no FDA-approved equivalent exists, or solely for cost?
4. Has the prescriber reviewed baseline labs consistent with Endocrine Society criteria before initiating therapy?

None of these questions would have produced a satisfactory answer in the BALCO context. Every legitimate modern TRT patient deserves answers to all four.

Key Takeaways on the Bonds Case for Clinicians and Patients

The Bonds/BALCO story is not a referendum on compounded testosterone as a category. It is a case study in what happens when compounding operates outside any regulatory structure, with substances designed to evade detection rather than treat disease.

Testosterone remains one of the most studied hormones in medicine. The 2018 Endocrine Society guideline, the TRAVERSE trial, and decades of pharmacokinetic data on branded injectables and gels give clinicians clear guardrails. Compounded testosterone from accredited pharmacies fills genuine gaps, particularly for patients requiring non-standard concentrations or formulations, when used under those same guardrails.

The Cream and the Clear were neither medicine nor therapy. They were tools built for a specific purpose. That purpose had nothing to do with restoring a hormone to its normal range.